4. Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
Findlay, J.M.#, Castro-Giner, F.#, Makino, S.#, Rayner, E.#, Kartsonaki, C., Cross, W., Kovac, M., Ulahannan, D., Palles, C., Gillies, R.S., MacGregor, T.P., Church, D., Maynard, N.D., Buffa, F., Cazier, J.-B., Graham, T.A., Wang, L.-M., Sharma, R.A., Middleton, M. & Tomlinson, I.*
University of Oxford, Churchill Hospital, Oxford Institute for Radiation Oncology, Queen Mary University of London, University of Birmingham, John Radcliffe Hospital, Oxford NIHR Comprehensive Biomedical Research Centre.
8.Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer
Lote, H.#, Spiteri, I.#, Ermini, L.#, Vatsiou, A., Roy, A., McDonald, A., Maka, N., Balsitis, M., Bose, N., Simbolo, M., Mafficini, A., Lampis, A., Hahne, J., Trevisani, F., Eltahir, Z., Mentrasti, G., Findlay, C., Kalkman, E.A.J., Punta, M.* & Valeri, N.*
The Institute of Cancer Research, The Royal Marsden NHS Trust, The Institute of Cancer Research, Crosshouse Hospital, Beatson West of Scotland Cancer Centre, Southern General Hospital, Crosshouse Hospital, ARC-NET Research Centre University of Verona, University of California San Francisco, Department of Psychology, Arizona State University, The Institute of Cancer Research, University of Padua.
10. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I, Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications
Marginean, C.* & Melosky, B.
University of Ottawa, University of British Columbia.